LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Bespak – 21.05.2025
Stoelzle – 15th May 2025

MacroGenics to cut workforce, close satellite sites

MacroGenics has initiated cost-saving measures through a corporate restructuring, announcing job cuts and the closure of two satellite facilities.

The planned measures include an approximate 15% workforce reduction in employees and the closure of two satellite sites — a Brisbane, California-based research site and a smaller-scale, non-commercial GMP manufacturing site in Rockville, Maryland.

This comes on the heels of last month’s trial closure. The Maryland-based biotech shuttered the phase 2 trial assessing its B7-H3-directed mAb in combination with either retifanlimab or tebotelimab in the first-line treatment of patients with head and neck cancer after seven of the 62 participants died.

Now, MacroGenics is looking to funnel its resources toward its most innovative pipeline candidates.

“In an effort to prioritize our pipeline of product candidates and reduce our spending, we have previously announced the termination of multiple studies. Today, we are taking additional decisive action to extend our cash runway and put MacroGenics in a stronger position to execute on our prioritized programs,” said Scott Koenig, MacroGenics president and CEO.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025